ProCE Banner Activity

Antiviral Agents for Nonhospitalized Patients With COVID-19

Multimedia
Hear expert insights on the use of IV and oral antiviral agents for the treatment of nonhospitalized patients with COVID-19.

Released: January 06, 2022

Expiration: January 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS

Director, Doherty Institute
Melbourne Laureate Professor
Director, Cumming Global Centre for Pandemic Therapeutics
Head, Department of Infectious Diseases
The University of Melbourne
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.